AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC

This article was originally published here

Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy across 54 countries, including the US, the European Union,

The post AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply